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Introduction {#sec1}
============

Pluripotency is defined as a cell's ability to differentiate into all somatic cell types. Two different pluripotent cell states have been proposed, which are commonly termed naïve and primed pluripotency. Mouse embryonic stem cells (ESCs) are derived from the inner cell mass (ICM) of developing embryos and have the ability to colonize preimplantation embryos after injection ([@bib33], [@bib12]). This is a hallmark feature of naive pluripotency, but such pluripotency is not necessarily the first pluripotent state in development, as mouse ESCs correspond to day-4.5 and not day-3.5 ICMs ([@bib4]). While scientists try to define the naive pluripotent state in humans ([@bib10]), it appears that the culture conditions of a pluripotent state corresponding to day-3.5 mouse embryos are yet to be defined.

In contrast to ESCs, epiblast stem cells (EpiSCs), which are derived from the epiblast of postimplantation embryos, can readily form teratomas and colonize embryos after being injected into the postimplantation epiblast ([@bib24]). However, when cultured under standard conditions, EpiSCs rarely, if at all, contribute to embryo development after being injected into preimplantation embryos ([@bib6], [@bib44], [@bib20]). These features are commonly considered to be the hallmark of primed pluripotency.

EpiSCs depend on basic fibroblast growth factor (bFGF) and Activin A signaling for maintaining pluripotency, while mouse ESCs require LIF together with inhibition of GSK3beta and fibroblast growth factor/extracellular-signal-regulated kinase (FGF/ERK). Mouse ESCs form small, compact, three-dimensional colonies, whereas EpiSCs grow as large, flat colonies. A small number of transcription factors that are highly expressed in ESCs, but not in EpiSCs, have been found to reprogram EpiSCs into ESCs ([@bib42], [@bib14], [@bib17], [@bib40], [@bib16], [@bib19], [@bib13]). Other studies have reported that the expression of transgenes is not required, and that EpiSCs could be converted into ESCs by a change in the culture conditions alone ([@bib2], [@bib15], [@bib22], [@bib8], [@bib47]).

The existence of at least one more distinct pluripotent state was previously revealed by our study, showing that EpiSC cultures display features of both early- and late-stage mouse epiblasts ([@bib20]). This work was prompted by the finding that EpiSCs display heterogeneity within a population ([@bib45], [@bib20]) and between different cell lines ([@bib3]). Part of this heterogeneity is probably due to the broad developmental window of derivation. In this regard, it has been suggested that early-stage EpiSCs are susceptible to cellular reprogramming toward an ESC-like state, whereas late-stage EpiSCs are recalcitrant to this process ([@bib20], [@bib3], [@bib23]). However, the majority of EpiSCs functionally display features of late-stage postimplantation epiblasts.

Using a pteridine-derived inhibitor, which we discovered previously ([@bib52]), we here show that inhibition of casein kinase 1alpha (CK1alpha) can promote the efficient conversion of recalcitrant EpiSCs into ESC-like cells. Furthermore, we demonstrate that the conversion is mediated by the combined activation of WNT signaling and attenuation of transforming growth factor beta (TGFbeta) signaling, resulting in the activation of the ESC pluripotency gene regulatory network. These findings provide mechanistic insights into the molecular switch governing the transition between distinct pluripotent states.

Results {#sec2}
=======

Triamterene Induces Conversion of Late-Stage EpiSCs {#sec2.1}
---------------------------------------------------

Two Oct4 reporter lines (GOF18, which harbors all known Oct4 regulatory elements, and OG2, which lacks the proximal enhancer; PE) were used to study the different states of pluripotency ([@bib49]) ([Figure 1](#fig1){ref-type="fig"}A). ESCs of both reporter lines express GFP when cultured under ESC culture conditions ([@bib3], [@bib20]). The corresponding EpiSCs, when cultured under EpiSC conditions, do not express GFP, except for a small subpopulation previously shown to contribute to the formation of chimeras ([@bib20]). Both Oct4-GFP-negative GOF18 EpiSCs and OG2 EpiSCs were found to be recalcitrant to 2i/LIF-based ESC conversion, which is consistent with findings of previous reports ([@bib3], [@bib20]) ([Figure 1](#fig1){ref-type="fig"}A, upper).

In our initial screen, triamterene (TR) was identified using unsorted GOF18 EpiSCs. Here, we tested the effect of TR on the recalcitrant Oct4-GFP-negative fraction of the GOF18 EpiSC line, the EpiSC line OG2 ([Figure 1](#fig1){ref-type="fig"}), and the extremely recalcitrant cell lines T9 and C1a1 ([@bib3]) ([Figure S1](#mmc1){ref-type="supplementary-material"}). After culturing the Oct4-GFP-negative fraction with TR for 7 days, more than 30% were found to become GFP positive, even under EpiSC culture conditions ([Figure 1](#fig1){ref-type="fig"}A, bottom left). Similar results were obtained with the EpiSC line OG2 ([Figure 1](#fig1){ref-type="fig"}A, bottom right). In contrast, applying stringent mESC conditions alone (2i/LIF) failed to revert the different late-stage EpiSCs to a putative naive state ([Figure 1](#fig1){ref-type="fig"}A, upper).

Clonal lines from the TR-reverted GOF18 ESC-like cells (TR-GOF18) expressed ESC-specific markers, such as *Rex1*, *Stella*, *Klf2*, *Klf4*, and *Esrrb* ([Figure 1](#fig1){ref-type="fig"}B). In contrast, the expression of genes typically expressed in EpiSCs, such as *T-brachyury*, *Fgf5*, and *Fgf8*, was reduced in TR-induced cells. Most importantly, global gene expression analysis showed obvious assimilation of the gene expression profiles of TR-converted cells and ESCs ([Figure 1](#fig1){ref-type="fig"}C, middle; see also [Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}B).

We then assessed the ability of TR to convert EpiSC lines (T9 and C1a1), which are especially resistant to media-induced conversion using 2i/LIF ([@bib3]). We found that TR efficiently induces the reactivation of ESRRB and KLF4 proteins in T9 and C1a1 EpiSCs and promotes a change in colony morphology to small dome-shaped colonies ([Figure 1](#fig1){ref-type="fig"}D). The relative conversion efficiency of TR for these cell lines was measured based on the expression of the pluripotency marker *PECAM1*/CD31 ([Figure S1](#mmc1){ref-type="supplementary-material"}A). After treatment with TR, the T9 and C1a1 cell lines expressed *PECAM1* at significantly lower levels than the other two cell lines ([Figure S1](#mmc1){ref-type="supplementary-material"}A). The lower conversion rates of the T9 and C1a1 EpiSCs may partly be due to spontaneous differentiation even under EpiSC culture conditions (see differentiated areas in [Figures 1](#fig1){ref-type="fig"}D, [S1](#mmc1){ref-type="supplementary-material"}B, and [S3](#mmc1){ref-type="supplementary-material"}B for early differentiation markers, such as *Fgf5* and *Fgf8*).

The effectiveness of TR in reinstating ESC pluripotency in EpiSCs was further tested using an X-Chromosome-GFP reporter in female EpiSCs ([@bib18]). This reporter had been previously shown to faithfully discriminate between ESCs and EpiSC-like cells, as this transgene specifically becomes reactivated in the naive state ([@bib21]).

The derivation of X-GFP EpiSCs has been previously described ([@bib14]). Hence, an induction of ESC pluripotency should lead to X chromosome reactivation, and, conversely, the expression of X-GFP would be indicative of a successful reversion of these cells. Culturing these EpiSCs in TR-containing media changed the morphology of these cells toward that of ESC-like colonies and, indeed, successfully promoted the reactivation of X-Chr-GFP and expression of ESRRB protein in these cells ([Figure 1](#fig1){ref-type="fig"}E).

During the conversion of GOF18 or OG2 EpiSCs with TR, the first dome-shaped Oct4-GFP-positive colonies appeared after 4 days. It was unclear whether TR was required throughout the whole culture period or whether a shorter exposure of TR would enable EpiSCs to convert under 2i/LIF conditions. To address this, sorted Oct4-GFP-negative E3 EpiSCs were treated with TR under EpiSC conditions for varying time periods, followed by further culturing under the 2i/LIF condition ([Figure S1](#mmc1){ref-type="supplementary-material"}C). We found that pretreatment with TR even for 3 days followed by 2i/LIF did not produce any GFP-positive colonies. On the fourth day of TR treatment, the first Oct4-GFP-positive colonies appeared. However, even after 4 days, 2i/LIF did not have any effect on the number of colonies, as the medium lacking both TR and 2i/LIF gave the same number of colonies. We therefore concluded that TR had to be present for 6 days in order for EpiSCs to undergo efficient conversion to an ESC-like state ([Figure S1](#mmc1){ref-type="supplementary-material"}C).

Taken together, the presence of TR during a period of 6 days induced the efficient conversion of late-stage EpiSCs toward a cellular state that is similar to that of ESCs.

PD0325901 Stabilizes the TR-Induced Transition to ESC Pluripotency {#sec2.2}
------------------------------------------------------------------

Although TR-converted cells and ESCs are quite similar, even clonal populations of E3 ESC-like cells always contained some Oct4-GFP-negative cells, which were not observed in ESCs cultured in KO-DMEM/KOSR (KO serum replacement)/LIF. We took this as an indication that TR on did not fully establish, and/or did not sufficiently maintain, ESC pluripotency ([Figure 2](#fig2){ref-type="fig"}A; compare left and middle). Analyses of gene expression and promoter methylation of ICM marker genes in these two TR-GOF18 populations showed that the Oct4-GFP-positive cell population more closely resembled ESC-like features than the Oct4-GFP-negative population. In fact, the latter cell fraction was more similar to EpiSCs ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B).

To achieve homogeneous and complete conversion of EpiSCs into ESC-like cells, we treated the TR-converted cells with a selected set of chemical inhibitors known to support ESC self-renewal, as well as with a collection of compounds synthesized in-house ([@bib34]). We found that culturing the TR-converted cells in KO-DMEM/KOSR/LIF together with the MEK inhibitor PD0325901 (PD) dramatically increased the proportion of Oct4-GFP-positive cells after only 48 hr ([Figure 2](#fig2){ref-type="fig"}A; compare middle and right). TR/PD-converted cells and ESCs were indistinguishable with respect to cell morphology, growth characteristics, alkaline phosphatase (AP) activity, and Oct4-GFP expression ([Figure S2](#mmc1){ref-type="supplementary-material"}C). At the molecular level, ESC-specific markers were (re-)expressed, while EpiSC markers were reduced in TR/PD-converted cells ([Figure 2](#fig2){ref-type="fig"}B). In contrast to EpiSCs, colonies of TR/PD-converted cells exhibited homogeneously expressed protein levels of SOX2, NANOG, and STELLA ([Figure 2](#fig2){ref-type="fig"}C).

ESCs preferentially use the distal enhancer (DE) to drive *Oct4* expression, while EpiSCs use the PE ([@bib44], [@bib49]). Using a luciferase assay, we compared the activity of the *Oct4* enhancer in the reverted cells with that of ESCs and EpiSCs. The PE/DE ratio in TR/PD-reverted cells was tilted toward the preferential use of the *Oct4* DE, like ESCs but unlike EpiSCs ([Figure 2](#fig2){ref-type="fig"}D). In accordance, TR/PD cells exhibited a global gene expression pattern that closely resembled that of ESCs ([Figure 2](#fig2){ref-type="fig"}E; see also [Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}B).

We next assessed the responsiveness of the TR/PD-reverted cells to ESC- and EpiSC-related signaling pathways ([Figure S2](#mmc1){ref-type="supplementary-material"}D). In order to propagate, EpiSCs depend on TGFbeta/SMAD2/3 signaling, whereas ESCs require stimulation of the LIF/STAT3 pathway. Inhibition of LIF/STAT3 signaling in ESCs was found to induce differentiation, i.e., pluripotency markers were downregulated and early differentiation markers were upregulated, compared with the untreated control ([Figure S2](#mmc1){ref-type="supplementary-material"}D, left; see ESC+JAKi). In contrast, inhibition of TGFbeta/SMAD2/3 signaling in EpiSCs induced differentiation ([Figure S2](#mmc1){ref-type="supplementary-material"}D, right; see EpiSC+SB). Upon inhibition of these two pathways, TR/PD cells reacted, in both cases, similarly to ESCs and differently from EpiSCs, indicating a switch in the signaling pathways toward those related to ESC pluripotency ([Figure S2](#mmc1){ref-type="supplementary-material"}D; see TR/PD+JAKi in left and TR/PD+SB in right). Notably, in both cases, TR-converted cells showed a more moderate response than ESCs and TR/PD-converted cells, again suggesting that TR alone primes EpiSCs for a complete switch of cell states ([Figure S2](#mmc1){ref-type="supplementary-material"}D; see TR-GOF18+JAKi in left and TR-GOF18+SB in right).

Germline Competence Is Restored in TR/PD-Converted Cells {#sec2.3}
--------------------------------------------------------

The converted cells were compared to EpiSCs and ESCs by global gene expression analysis. The heatmaps of TR/PD cells were found to be very similar to those of ESCs ([Figure 3](#fig3){ref-type="fig"}A), which was also confirmed by hierarchical clustering analysis ([Figure S3](#mmc1){ref-type="supplementary-material"}A). The most differentially expressed genes between TR-converted and TR/PD cells give insight into the specific genetic changes that distinguish the two cell types ([Figure S3](#mmc1){ref-type="supplementary-material"}B). For example, the ICM markers *Dppa5*, *Esrrb*, *Dppa4*, *Klf2*, and *Nr5a2* were expressed in TR-GOF18 cells at levels comparable to those in ESCs. Other ICM markers, such as *Tcl1*, *Tbx3*, and *Klf4*, were also strongly induced in TR-GOF18 cells compared with EpiSCs but reached the expression levels of ESCs only upon inhibition of the MEK pathway (addition of PD). MEK inhibition also resulted in the suppression of early differentiation markers, such as *Fgf5* and *Fgf8*, which were elevated in TR-GOF18 cells (or a subset thereof).

We then assessed whether the aforementioned switch in gene expression was accompanied by a global change in the methylation state of TR/PD-converted cells. Consistent with the gene expression data ([Figures 1](#fig1){ref-type="fig"}B and [2](#fig2){ref-type="fig"}B), the endogenous *Oct4* promoter was found to be completely unmethylated in both ESCs and EpiSCs, while the Oct4-GFP transgene promoter was mainly unmethylated in ESCs and highly methylated in EpiSCs ([Figure 3](#fig3){ref-type="fig"}B). In TR/PD cells, the Oct4-GFP transgene promoter was basically unmethylated, whereas in TR-converted cells, the transgene promoter was only partially unmethylated. Demethylation was also observed for other marker genes analyzed in TR/PD-converted cells ([Figure 3](#fig3){ref-type="fig"}B).

Following global gene expression and methylation analysis, we sought to functionally characterize the reverted cells using in vivo differentiation assays. TR/PD-converted cells were found to give rise to teratomas containing tissues of all germ layers ([Figure 3](#fig3){ref-type="fig"}C). Most importantly, upon injection into blastocysts, TR/PD-converted cells showed successful integration into the ICM and, consequently, contribution to the germline ([Figure 3](#fig3){ref-type="fig"}D).

The TR Derivative Epiblastin A Is a Potent Inducer of ESC Pluripotency in EpiSCs {#sec2.4}
--------------------------------------------------------------------------------

Kinase profiling and subsequent gene knockdown (KD) experiments had revealed that CK1alpha is a target enzyme in TR-induced ESC conversion, and structure-activity relationship analyses with chemically synthesized derivatives of TR yielded Epiblastin A as the most potent TR-derived CK1 inhibitor ([@bib52]).

Next, the ability of Epiblastin A to promote the reversion of EpiSCs was analyzed in further detail. Among the set of compounds examined, Epiblastin A was found to exhibit the highest conversion efficiency based on Oct4-GFP and *PECAM1* reactivation, almost 2-fold higher than TR ([Figure 4](#fig4){ref-type="fig"}A). CH and sodium butyrate had a negligible effect on the reactivation of Oct4-GFP and *PECAM1* ([Figure 4](#fig4){ref-type="fig"}A). This is a compelling finding, as Epiblastin-A-converted cells exhibited similar cell morphology; Oct4-GFP expression; AP immunoreactivity; protein levels of SOX2, NANOG, and STELLA; and gene expression profiles as ESCs ([Figures 4](#fig4){ref-type="fig"}B--4D). Most importantly, Epiblastin A/PD-converted cells regained the ability to contribute to chimera development when injected into blastocysts ([Figure 4](#fig4){ref-type="fig"}E).

CK1 Inhibition Promotes the Activation/Maintenance of the ESC Pluripotency Gene Regulatory Network {#sec2.5}
--------------------------------------------------------------------------------------------------

The next question was how the inhibition of CK1 influenced the expression of known pluripotency factors. To address this point, EpiSCs were treated with TR for 2, 4, 6, and 8 days. Notably, the expression of *Klf2*, *Nanog*, and *Esrrb* was upregulated from day 2 onward, albeit with different dynamics ([Figure 5](#fig5){ref-type="fig"}A). After 8 days of treatment with TR, expression levels of *Nanog* and *Esrrb* even exceeded those in ESCs. This result was recapitulated using D4476, an independent inhibitor of CK1 ([Figure S4](#mmc1){ref-type="supplementary-material"}A).

Next, the role of *Klf2*, *Nanog*, and *Esrrb* during Epiblastin-A-based conversion was determined by small hairpin RNA (shRNA)-based KD experiments ([Figures 5](#fig5){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}B). *Nanog* KD, by far, had the strongest effect, as it essentially abolished reversion by Epiblastin A. *Klf2* KD also significantly reduced reversion efficiencies, suggesting critical roles for both Nanog and Klf2 in the process of reprogramming. *Esrrb* KD had a less dramatic effect, reducing the action of Epiblastin A by about 30% ([Figure 5](#fig5){ref-type="fig"}B).

As CK1 inhibitors have an impact on key pluripotency genes during the reversion of EpiSCs into ESC-like cells, we sought to test whether Epiblastin A and TR can affect self-renewal based on their ability to maintain the pluripotency gene regulatory network. High levels (5 μM and above) of Epiblastin A or TR were found to be toxic (data not shown), and N2B27 medium alone was not permissive for ESC self-renewal. However, following a titration experiment, an optimal working concentration of 2 μM Epiblastin A was found to promote clonal expansion of ESCs in N2B27. Addition of either LIF or PD to Epiblastin-A-supplemented media increased the cells' ability to self-renew, whereas addition of CH to Epiblastin-A-supplemented media decreased their ability ([Figure 5](#fig5){ref-type="fig"}D).

Upon switching to EpiSC media (based on N2B27/Activin A/bFGF), ESCs acquire properties of primed pluripotency ([@bib17]). Nanog-GFP ESCs show progressive downregulation of Nanog-GFP under this condition ([@bib7], [@bib26]). WNT signaling has been reported to prevent the commitment of ESCs into EpiSCs ([@bib43]). Consistent with this observation, we found that downregulation of Nanog-GFP during EpiSC differentiation was blocked by the addition of TR, with an efficacy comparable to that of the WNT agonist CH ([Figure 5](#fig5){ref-type="fig"}C). On the other hand, ESCs cultured in the presence of serum and LIF are known to exhibit transcription factor heterogeneity, coinciding with the presence of cells with different self-renewal abilities ([@bib7]). To test the ability of TR to maintain the homogeneous expression of ICM transcription factors, we used the two reporter lines Nanog-GFP and Esrrb-Tomato. TR treatment induced a high and homogeneous expression of Nanog-GFP and Esrrb-Tomato for the duration of the assay, whereas untreated controls gave rise to Nanog-GFP-negative and Esrrb-Tomato-negative cells ([Figure S4](#mmc1){ref-type="supplementary-material"}C).

Inhibition of CK1alpha Results in Simultaneous Activation of WNT Signaling and Inhibition of TGFbeta/SMAD2 Signaling {#sec2.6}
--------------------------------------------------------------------------------------------------------------------

We next turned our attention to the mechanism underlying the inhibition of CK1. Signaling pathways known to be involved in ESC pluripotency were analyzed by using CK1 inhibitors. We found that Epiblastin A prevented phosphorylation of BCATENIN and SMAD2 ([Figure 6](#fig6){ref-type="fig"}A). It also affected STAT3 phosphorylation, probably due to inhibition of PI3K, as identified by kinase profiling. In contrast, ERK (and, consequently, probably the entire ERK pathway) was not affected ([Figure 6](#fig6){ref-type="fig"}A).

Following the inhibition of phosphorylation of BCATENIN, we further analyzed the effect of Epiblastin A and TR on the WNT pathway. To determine the enrichment of factors associated with signaling pathways, a Gene Ontology enrichment analysis was performed with the genes that were significantly upregulated within 12 hr of treatment of EpiSCs with TR. Based on this analysis, the WNT receptor signaling pathway clearly ranked at the top of significantly enriched "biological process" terms ([Figure S5](#mmc1){ref-type="supplementary-material"}A). The known WNT/TCF (T-cell-factor) target genes *Axin2*, *Cdx1*, and *T-brachyury* were upregulated upon TR treatment ([Figure S5](#mmc1){ref-type="supplementary-material"}B) ([@bib27]). We then performed the TOPFlash TCF-Luciferase assay to assess the WNT-inducing activity of Epiblastin A and found that Epiblastin A was more active than CH ([Figure 6](#fig6){ref-type="fig"}B).

Then we tested whether the positive effect of Epiblastin A treatment on ESC self-renewal was dependent on the WNT/BCATENIN pathway ([Figure 5](#fig5){ref-type="fig"}D). To this end, we used an ESC line in which both BCATENIN alleles had been floxed and that carried a CreERT2 cassette inserted into the ROSA26 locus (BCATENIN^*fl/fl*^) ([@bib5], [@bib45]). Treatment of BCATENIN^*fl/fl*^ ESCs with 4-hydroxytamoxifen induced the deletion of both BCATENIN alleles, generating BCATENIN^−*/*−^ ESCs ([Figure 6](#fig6){ref-type="fig"}D, western blot). BCATENIN^−*/*−^ ESCs were unable to self-renew in the presence of CH/PD (2i) or CH/LIF ([Figure 6](#fig6){ref-type="fig"}D, right). The combined presence of only PD and LIF supports self-renewal in the absence of BCATENIN, albeit with decreased efficiency ([@bib48]). Interestingly, although self-renewal efficiency was equally diminished by the depletion of BCATENIN, Epiblastin A was still capable of sustaining the ESC state ([Figure 6](#fig6){ref-type="fig"}D, right).

Finally, we assessed the potential of Epiblastin A and TR to modulate the WNT pathway in vivo. Zebrafish embryos 7--48 hr postfertilization (hpf) were kept in the presence of Epiblastin A or TR. At 48 hpf, zebrafish embryos exhibited a phenotype characteristic of WNT overactivation during this period of development, including impaired development of the eyes, forehead, and tail ([Figure 6](#fig6){ref-type="fig"}C).

P-SMAD2 was affected by both Epiblastin A and TR ([Figure 6](#fig6){ref-type="fig"}A). Therefore, we determined the role of SMAD2 during the reversion process. We hypothesized that Epiblastin A and TR might act by inhibiting the phosphorylation of both BCATENIN and SMAD2; therefore, we simulated this action by using CH together with SB431542 (SB), an inhibitor of TGFbeta/SMAD2/3 signaling. Interestingly, while CH or SB promoted the differentiation of EpiSCs, when combined, they gave rise to ESC-like colonies expressing Oct4-GFP and ICM marker genes at levels comparable to those of ESCs ([Figures 6](#fig6){ref-type="fig"}E and 6F). Just like with Epiblastin A or TR, the conversion with CH/SB took 4--6 days and could even be achieved under EpiSC culture conditions.

A role for different CK1 isoenzymes in BCATENIN and SMAD2 phosphorylation had been reported by earlier studies ([@bib1], [@bib46]). We had previously found that KD of CK1alpha gave rise to a significant percentage of Oct4-GFP-positive cells compared with KD of either CK1epsilon or CK1delta. To determine whether a particular CK1 isoenzyme is involved in BCATENIN and SMAD2 phosphorylation, we performed an shRNA (short-hairpin-RNA)-based KD of CK1alpha, CK1delta, and CK1epsilon in EpiSCs ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Western blot analysis revealed that KD of either CK1alpha or CK1epsilon affected the phosphorylation of both BCATENIN and SMAD2 ([Figure S5](#mmc1){ref-type="supplementary-material"}D). As TR did not inhibit GSK3beta and ALK ([@bib52]), these findings suggest that Epiblastin A and TR act on BCATENIN and SMAD2 phosphorylation via CK1alpha and CK1epsilon. Having obtained a significant population of Oct4-GFP-positive cells after KD of CK1alpha in E3 EpiSCs, we then derived and stably maintained a clonal cell line from this population. These cells strongly resembled ESCs in morphology, growth behavior, and Oct4-GFP expression. Global gene expression profiling revealed a gene expression pattern indistinguishable from that of ESCs ([Figure S5](#mmc1){ref-type="supplementary-material"}E).

Finally, we sought to clarify the role played by LIF in the reversion process. TR was found to inhibit PI3K, which may explain the blocked STAT3 phosphorylation, pointing toward a redundancy of this pathway during conversion ([Figure 6](#fig6){ref-type="fig"}A). Moreover, ESCs could be maintained with Epiblastin A alone, i.e., without LIF ([Figure 5](#fig5){ref-type="fig"}D), and SB/CH could equally maintain ESCs without LIF (data not shown). To categorically determine whether LIF/STAT3 signaling is involved in Epiblastin-A-mediated self-renewal, we used *Stat3*^−*/*−^ ESCs. These ESCs require CH/PD (2i) supplementation for propagation ([@bib50]). In the absence of *Stat3*, Epiblastin-A-mediated self-renewal was severely reduced in the presence of either LIF or CH ([Figure S5](#mmc1){ref-type="supplementary-material"}F). In contrast, the dual inhibition of ERK and CK1 (N2B27/PD/Epiblastin A) promoted the robust propagation of *Stat3*^−*/*−^ ESCs, for more than 2 months ([Figure S5](#mmc1){ref-type="supplementary-material"}F). *Stat3*^−*/*−^ ESCs cultured for more than 2 months in PD/Epiblastin A were found to retain robust expression of OCT4, NANOG, ESRRB, and KLF4 proteins and to give rise to chimeric mice after blastocyst injection ([Figures S5](#mmc1){ref-type="supplementary-material"}G and S5H). Taken together, our data suggest a concise mechanism of action for Epiblastin A and TR that is based on BCATENIN and SMAD2 modulation via inhibition of CK1alpha ([Figure 6](#fig6){ref-type="fig"}G).

Discussion {#sec3}
==========

As previously shown, EpiSCs are heterogeneous within and among cell lines ([@bib3], [@bib20], [@bib45], [@bib2]). Only a small subpopulation of EpiSCs displays features of the early postimplantation epiblast ([@bib2], [@bib20]), whereas the vast majority of EpiSCs functionally represent cells of late-stage postimplantation epiblast. Early-stage EpiSCs are susceptible to media-induced reversion into cells of an ESC-like state, whereas late-stage EpiSCs are refractory to this process ([Figure 1](#fig1){ref-type="fig"}A) ([@bib3], [@bib20]). In this study, we show that a small molecule compound, which was previously discovered in our laboratory, is capable of inducing the reversion of both early- and late-stage EpiSCs into ESC-like cells, and we herein describe its underlying mechanism of action. To our knowledge, this is the first study showing the robust conversion of late-stage EpiSCs into ESCs through chemical means only.

The conversion of EpiSCs into ESC-like cells by Epiblastin A and TR displays several striking features. After a relatively short exposure period to induce ESC pluripotency (6--8 days), cells converted by Epiblastin A or TR could be clonally expanded and maintained in LIF-supplemented ESC medium, without needing to further add either inhibitor. Notably, we found that TR induces the expression of Oct4-GFP in EpiSC medium in the absence of exogenous LIF. This likely occurs due to the presence of LIF in MEF (mouse embryonic fibroblast)-conditioned medium. However, Epiblastin A and TR were also found to inhibit PI3K-mediated STAT3 phosphorylation, indicating a redundancy of this pathway during the conversion process ([Figure 6](#fig6){ref-type="fig"}A).

Activation of the FGF/ERK pathway predisposes ESCs to differentiation ([@bib15], [@bib29]). Conversely, ERK inhibition, in combination with LIF and/or CH, supports the maintenance of undifferentiated ESCs ([@bib50]). This is consistent with our observation that ERK inhibition in TR-converted cells finalizes and/or stabilizes the transition of these cells to ESC pluripotency ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}).

Several kinase inhibitors have been reported either to support the generation of induced pluripotent stem (iPS) cells or to promote the conversion to ESC-like pluripotency ([@bib50], [@bib30], [@bib38], [@bib25], [@bib32]). Notably, TR did not inhibit GSK3beta, MEK/ERK, or ALK4/5, which are all targets of inhibitors that promote the reversion of EpiSCs into ESC-like cells ([@bib15], [@bib51]). This observation suggested that TR must be working through the regulation of a different kinase.

Kinase profiling revealed that Epiblastin A and TR inhibited CK1 isoenzymes, and KD of CK1alpha gave rise to Oct4-GFP-positive colonies; inhibiting either CK1epsilon or CK1delta had no effect at all. These cells had a gene expression profile that was indistinguishable from that of ESCs, and KD of CK1alpha resulted in reduced BCATENIN and SMAD2 phosphorylation, thus further substantiating a role for CK1alpha in the reprogramming process ([Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D).

CK1 family members are known to exert both negative and positive effects on WNT signaling ([@bib35]). Potential contact points for negative WNT regulation via CK1-mediated phosphorylation include BCATENIN ([@bib1], [@bib31]), APC ([@bib37]), and LRP5/6 ([@bib41]). However, members of the CK1 family are also known to be involved in numerous other processes, including p53 and E-cadherin modifications, nuclear-cytoplasmic shuttling of transcription factors, and TGFbeta signaling ([@bib36], [@bib46], [@bib28], [@bib11]). It is also known that TR inhibits dihydrofolate reductase, acting as an antifolate due to the common pteridine structure of these two proteins ([@bib9], [@bib39]). The resulting inhibition of DNA synthesis could explain the toxicity of Epiblastin A and TR when used in higher concentrations.

We confirmed the agonistic effect of Epiblastin A and TR on the WNT pathway both in vitro and in vivo. Furthermore, we showed that both Epiblastin A and TR simultaneously modulate WNT/BCATENIN and TGFbeta/SMAD2 signaling by inhibiting CK1alpha. Accordingly, we could also demonstrate that simultaneous activation of the WNT pathway and inhibition of SMAD2 signaling can mimic the Epiblastin-A- or TR-based reprogramming mechanism, in contrast to perturbing the two pathways individually ([Figures 6](#fig6){ref-type="fig"} and [S5](#mmc1){ref-type="supplementary-material"}). That is why neither SB nor CH could convert EpiSCs to ESC pluripotency.

Treatment of EpiSCs with TR coincided with strong upregulation of the key ESC-specific pluripotency markers *Klf2*, *Nanog*, and *Esrrb* ([Figure 5](#fig5){ref-type="fig"}A). Interestingly, KD of *Klf2* or *Nanog* significantly impaired Epiblastin-A/TR-based EpiSC reversion, highlighting the importance of these factors during this process ([Figure 5](#fig5){ref-type="fig"}B). KD of *Esrrb* reduced the number of Epiblastin-A-induced Oct4-GFP-positive cells by half ([Figure 5](#fig5){ref-type="fig"}B). However, shRNA probes for *Esrrb* were less efficient than those for *Nanog* and *Klf2* ([Figure S4](#mmc1){ref-type="supplementary-material"}B). These intrinsic factors may be important for the chemical-induced reversion of EpiSCs, consistent with previous reports that they are efficient in promoting conversion when expressed ectopically ([@bib13], [@bib40], [@bib19]).

Taken together, our results demonstrate not only that ESC pluripotency can be induced in late-stage EpiSCs, but also that this conversion can be made simple and very efficient. Moreover, our findings reveal insights into the mechanisms governing the transition between distinct states of pluripotency. This is of special interest, as we describe the conversion of the two extremes of pluripotency that have been defined to date. Notably, we introduce CK1alpha as a key player in the regulation of ESC pluripotency, through the direct modulation of WNT/BCATENIN and TGFbeta/SMAD2 signaling. These findings open the door to addressing numerous questions. For example, we can now determine whether the role of CK1 in the regulation of ESC pluripotency is conserved across species. Additionally, by means of CK1 inhibition and appropriate culture conditions, we now can define a pluripotent state that corresponds to day 3.5 ICMs.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

The derivation of EpiSC lines is described elsewhere ([@bib15]). EpiSCs were cultured on feeder-free dishes that had been precoated with fetal calf serum (FCS) for 15 min in MEF (CF1 mice)-conditioned medium. EpiSC medium before MEF conditioning consisted of DMEM/F12 (Gibco BRL) containing 20% knockout (KO) serum replacement (Gibco BRL), 2 mM glutamine, 1× nonessential amino acids, and 5 ng/ml bFGF. For conditioning, irradiated MEFs were seeded at a density of 5 × 10^4^ cells per square centimeter and incubated in EpiSC medium for 24 hr. The conditioned medium was filtered, and bFGF (5 ng/ml) was added (this was termed CM/FGF). EpiSCs were passaged using Accutase (Invitrogen) and seeded as single cells at approximately 15,000 cells per 6-cm dish. Medium was changed every 24 hr. ESCs, TR-GOF18, and TR/PD-converted cells were cultured on irradiated MEFs or on gelatin-coated plates in KO-DMEM medium containing 20% KO serum replacement, 2 mM glutamine, 1× nonessential amino acids, and LIF (1,000 U/ml). ESCs, TR-GOF18, and TR/PD-converted cells were passaged using trypsin (Invitrogen).

ESC Conversion of EpiSCs {#sec4.2}
------------------------

EpiSCs were dissociated using Accutase and plated as single cells either on γ-irradiated MEF feeder cells or on FCS-coated tissue culture plates at low density (≤10,000 cells per well of a six-well plate) and cultured overnight in MEF-conditioned EpiSC medium supplemented with bFGF. Depending on the cell line, ROCK (Rho-associated protein kinase) inhibitor could be used to ensure higher cell survival after single-cell dissociation with Accutase. The next day, the EpiSC medium was replaced by the conversion medium. If not otherwise indicated, the conversion medium consisted of MEF-conditioned EpiSC medium containing 2 μM TR or Epiblastin A without additional bFGF. Higher concentrations of the compounds (\>5 μM) were cytotoxic and increased cell death during conversion. The cells were cultured in the conversion medium for 8 days, and after the first 3 days, the medium was changed daily. OCT4-GFP-positive colonies usually started to appear on day 6. On day 8, the cells were dissociated with trypsin and replated at low density on MEF feeder cells or on a gelatin-coated cell culture dish in standard ESC medium supplemented with PD to allow for single-colony formation. For the first three to five passages, the newly formed ESC-like colonies were manually selected, dissociated with trypsin, and replated in a new culture dish.

Flow Cytometry {#sec4.3}
--------------

For fluorescence-activated cell sorting (FACS) and analysis, cell colonies were dissociated into single cells, as described earlier, resuspended in the corresponding culture medium at a cell density of approximately 5 × 10^6^ cells per milliliter, and then analyzed using a FACSAria Cell Sorter (BD Biosciences).

Luciferase Assay {#sec4.4}
----------------

For quantifying relative *Oct4* enhancer activity, the PE and the DE were PCR amplified from a GOF18 plasmid ([@bib49]) and cloned into pGL3-Promoter (Promega). ESCs, EpiSCs, TR-GOF18, and TR/PD-converted cells were grown under feeder-free conditions and transfected using Lipofectamine 2000. All cells were seeded as single cells following Amaxa nucleofection (∼2 million cells, 4 μg DNA, and program A-23) and assayed after 2 days. Values were normalized to the renilla and the empty vector signals.

Western Blot {#sec4.5}
------------

Western blot analyses were performed following a standard procedure. Proteins were separated by SDS-PAGE and transferred onto nitrocellulose membranes. The membranes were incubated with the antibodies raised against phospho-S33/S37/T41-BCATENIN (Cell Signaling Technology \[CST\], \#9561), phospho-S465/467-SMAD2 (CST, \#3101), SMAD2/3 (CST, \#3102), p-ERK (CST, \#4370), ERK (CST, \#9102), BCATENIN (BD Biosciences, C19220-050), phospho-STAT3 (Santa Cruz Biotechnology, sc-8059), and STAT3 (Santa Cruz, sc-482). Protein bands were visualized using ECL Prime Western Blotting Detection Reagent (GE Healthcare).
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![TR Induces ESC Conversion of Recalcitrant EpiSCs\
(A) Oct4-GFP expression after treatment with 2i/LIF (top) and TR (5 μM; bottom) for 7 days in sorted Oct4-GFP-negative GOF18 EpiSCs (left) and OG2 EpiSCs as measured by flow cytometry (FSC, forward scatter). The basal medium for the conversion with 2i/LIF was ESC medium (20% serum replacement in KO-DMEM) and, for the conversion with TR, EpiSC conditioned medium containing FGF2 and Activin A.\
(B) Comparison of gene expression patterns in ESCs, TR-GOF18 cells, and EpiSCs. The expression levels are normalized to those of unsorted E3 EpiSCs (the data represent mean ± SD of triplicates; n = 3).\
(C) Scatterplot of global gene expression microarrays comparing TR-GOF18 cells with ESCs (middle) and unsorted E3 EpiSCs (bottom). The comparison of unsorted E3 EpiSCs and ESCs (top) is shown as control. The black lines delineate the boundaries of 4-fold difference in gene expression levels. Genes highly expressed in TR-GOF18 cell samples compared with ESC samples are shown as red dots; those less expressed are shown as green dots. The positions of the pluripotent cell marker *Zfp42*/*Rex1* and the germ cell marker *Dppa3*/*Stella* are indicated as orange dots. The color bar to the right indicates the scattering density; the higher the scattering density, the darker the blue. The gene expression levels are depicted on log~2~ scale.\
(D) Immunofluorescence analysis for Klf4 and Esrrb proteins in recalcitrant EpiSC lines C1a1 (top) and T9 (bottom) following treatment with TR for 7 days (the scale bar represents 200 μm).\
(E) X chromosome reactivation and immunofluorescence analysis for Esrrb protein in female EpiSCs following treatment with TR for 7 days (the scale bar represents 200 μm).\
See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![MEK Inhibition in TR-Treated Recalcitrant EpiSCs Improves the Transition to ESC Pluripotency\
(A) Percentage of Oct4-GFP-positive cells in ESCs, TR-GOF18 cells, and TR/PD cells as measured by flow cytometry (forward scatter: FSC). TR-GOF18 represents a clonal cell line of TR-converted E3 EpiSCs, which was maintained under ESC culture conditions for more than 30 passages. The TR/PD represents a clonal cell line of TR-GOF18 cells after treatment with the MEK inhibitor PD (1 μM) for 2 days. The TR/PD cells were maintained under ESC culture conditions in the presence of PD.\
(B) Comparison of gene expression patterns in ESCs, TR-GOF18 cells, and TR/PD cells. The expression levels are normalized to those of unsorted E3 EpiSCs (the data represent mean ± SD of triplicates; n = 3).\
(C) Immunofluorescence analysis for Sox2, Nanog, and Stella (Dppa3) in ESCs, TR-GOF18 cells, EpiSCs, and TR/PD-converted cells. DAPI was used for nuclear staining (the scale bar represents 350 μm).\
(D) Luciferase assay showing the ratios of Oct4 enhancer activity in ESCs, TR-GOF18 cells, EpiSCs, and TR/PD-converted cells. The enhancer activities in EpiSCs and TR-GOF18 cells are normalized to the DE activity, which is set to 1. The enhancer activities in ESCs and TR/PD cells are normalized to the PE activity, which is set to 1. The relative luciferase activities were also normalized to the activity of an empty vector (the data represent mean ± SD of triplicates; n = 3; and p \< 0.001).\
(E) Scatterplot of global gene expression microarrays comparing TR/PD cells with ESCs. For control scatterplots, see [Figure 1](#fig1){ref-type="fig"}C. The black lines delineate the boundaries of 4-fold difference in gene expression levels. The genes highly expressed in TR/PD samples compared with ESC samples are shown as red dots; those less expressed are shown as green dots. The positions of the pluripotent cell marker *Zfp42*/*Rex1* and the germ cell marker *Dppa3*/*Stella* are indicated as orange dots. The color bar to the right indicates the scattering density; the higher the scattering density, the darker the blue color. The gene expression levels are depicted on log~2~ scale.\
See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Combined Treatment with a MEK Inhibitor and TR Restores Germline Competency in EpiSCs\
(A) Heatmap of global gene expression patterns in ESCs, TR-GOF18 cells, unsorted E3 EpiSCs, and TR/PD cells. The color bar at the top codifies the gene expression in log~2~ scale. The red and blue colors indicate high and low gene expression levels, respectively.\
(B) DNA methylation status of the promoter regions of ICM marker genes in ESCs, TR-GOF18 cells, unsorted E3 EpiSCs, and TR/PD cells was analyzed using bisulfite-sequencing PCR.\
(C) Representative image of a teratoma derived from TR/PD cells in a teratocarcinoma assay, together with representative tissues of ectodermal (skin epithelium), mesodermal (muscle), and endodermal (gut-like) lineages in teratomas obtained from TR/PD cells (the scale bar represents 50 μm).\
(D) Embryonic and germline contribution of TR/PD cells. The blastocyst injection using TR/PD cells was performed, and the contribution of the cells to the ICM (left; the scale bar represents 50 μm), midterm (E14.5) pups (middle), and germline (right; the scale bar represents 450 μm) was assessed. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![The TR Derivative Epiblastin A Is a Potent Inducer of ESC Pluripotency in EpiSCs\
(A) Percentage of Oct4-GFP and *PECAM1* (*CD31*) double-positive cells after 7 days of ESC conversion with Epiblastin A (5 μM), TR (5 μM), 2i (PD: 1 μM and CH: 3 μM), CH (3 μM), NaB (100 μM), and D4476 (20 μM) in unsorted GOF18 EpiSCs as measured by flow cytometry.\
(B) Morphology, Oct4-GFP, and ALP expression in Epiblastin A-GOF18 cells (left; the scale bars represent 300 μm).\
(C) Immunofluorescence analysis for Sox2, Nanog, and Stella (Dppa3) in Epiblastin A-GOF18 cells. DAPI was used for nuclear staining (right; the scale bar represents 300 μm).\
(D) Comparison of gene expression patterns in ESCs, Epiblastin A-GOF18 cells, and EpiSCs. The expression levels are normalized to those of EpiSCs (the data represent mean ± SD of triplicates; n = 3).\
(E) Chimeric mice derived from Epiblastin A-GOF18 cells after blastocyst injection.](gr4){#fig4}

![Casein Kinase 1 Inhibition Promotes the Activation/Maintenance of the ESC Pluripotency Gene Network\
(A) Time-course analysis for whole mRNA expression of *Klf2*, *Nanog*, and *Esrrb* in TR-treated EpiSCs. The gene expression levels are normalized to those of untreated EpiSC samples (the data represent mean ± SD of triplicates; n = 3).\
(B) Percentage of Oct4-GFP and *PECAM1* (*CD31*) double-positive cells after 6 days treatment with Epiblastin A, together with shRNA-based KD of *Esrrb*, *Nanog*, and *Klf2*, respectively, in GOF18 EpiSCs as measured by flow cytometry.\
(C) Differentiation of ESCs into EpiSCs is blocked by supplementation with TR. The flow-cytometry analysis of *Nanog*-GFP-positive cells during EpiSC differentiation (A/F) and in the presence of either Chiron or TR is shown (A, Activin A; F, bFGF). Black cell population represents non-fluorescent control cells). Puromycin selects for the expression of Nanog. The selection cassettes are part of the reporter construct that was knocked in into the Nanog locus.\
(D) Clonal assay of ESCs in the indicated culture conditions. The ESCs were plated onto gelatin-coated plates and cultured for 7 days, after which, the cells were stained for AP and counted (L, LIF; E, Epiblastin A).\
See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

![Epiblastin A/TR Treatment Simultaneously Activates WNT Signaling and Inhibits TGFbeta/SMAD2 Signaling\
(A) Western blot analysis showing the effects of Epiblastin A and Chiron on BCATENIN, SMAD2, STAT3, and ERK phosphorylation in EpiSCs. The cells were treated with either Epiblastin A or Chiron for 30 min. An additional experiment was performed using a BCATENIN KO cell line to prove specific binding to p-BCATENIN of the applied antibody (lower band indicated with an arrow).\
(B) Luciferase assay of TCF/Lef-mediated transcriptional activity in EpiSCs as a result of Epiblastin A and Chiron treatment. The Chiron was used as a positive control. The columns depict the TOP/FOP ratio (the data represent mean ± SD of triplicates; n = 3; and p \< 0.001).\
(C) Phenotypes of zebrafish embryos at 48 hpf. The embryos were allowed to grow in the presence of the indicated inhibitors from 7 hpf (the scale bar represents 500 μm).\
(D) Clonal assay of Bcatenin^fl/fl^ and Bcatenin^−/−^ ESCs in the indicated culture conditions. Bcatenin^fl/fl^ ESCs were plated at clonal density (600 cells) onto gelatin-coated plates and cultured for 7 days, after which, the cells were stained for AP and counted. To generate Bcatenin^−/−^, Bcatenin^fl/fl^ were plated as described earlier. After 48 hr, the cells were treated with 1 μM of 4-hydroxytamoxifen for 24 hr to induce the Cre excision of the floxed-Bcatenin. Western blot analysis demonstrates successful excision of Bcatenin after treatment with 4-hydroxytamoxifen (P, PD; C, CH; L, LIF; and E, Epiblastin A).\
(E) Morphology and Oct4-GFP expression in sorted Oct4-GFP-negative E3 EpiSCs treated for 6 days with the indicated inhibitors as measured by FACS (the scale bar represents 200 μm).\
(F) Real-time qPCR analysis of ICM marker gene expression in SB/CH-treated cells, EpiSCs, and ESCs. The gene expression levels are normalized to those of unsorted E3 EpiSC samples (the data represent mean ± SD of triplicates; n = 3).\
(G) Schematic model of the mechanism by which TR/Epiblastin A reverts recalcitrant EpiSCs into ESCs. See text for discussion.\
See also [Figure S5](#mmc1){ref-type="supplementary-material"}.](gr6){#fig6}
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